- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
* Exclusive event for 80 specially invited guests
* Highlight: Clinical efficacy of Nano-Cancer®-therapy now proven
* Growing investor interest in Nanostart and its protfolio companies
Marco Beckmann, CEO of Nanostart AG, the global nanotechnology investment company based in Frankfurt, will be presenting the company and its portfolio holdings to an audience of approx. 80 selected investors and analysts on November 5 in New York City's Manhattan Club.
The occasion for this special investor event is first and foremost the superb results of clinical trials reported by MagForce Nanotechnologies AG (ISIN DE000A0HGQF5), which is 77% owned by Nanostart. On November 3, MagForce announced the successful completion of its clinical trials demonstrating the efficacy of its Nano-Cancer® therapy in treating recurrent glioblastoma, a particularly malignant form of brain tumor. The median survival time was more than doubled in the patient group, far in excess of the study objective. These clinical trials thus conclusively demonstrated the efficacy of Nano-Cancer® therapy. The study also confirmed that the therapy is extremely well tolerated by patients compared to conventional therapies, with no significant side effects.
The presentation will take place as part of an evening program. Marco Beckman will be in the spotlight as the event's sole speaker, and guests will have ample time following the formal presentation to speak individually with him and to ask detailed questions.
Vanessa Mieschke, responsible for investor relations at Nanostart, commented: "With these superb results from its clinical trials, our majority-owned MagForce is entering into a new era. Large U.S. investors have been awaiting these results with anxious anticipation."
Disclaimer: This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector.
For more information, please click here
Dr. Hans Joachim Dürr
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
Copyright © NanostartIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016
Arrowhead to Present at Upcoming March Conferences March 1st, 2016
Researchers create a first frequency comb of time-bin entangled qubits: Discovery is a significant step toward multi-channel quantum communication and higher capacity quantum computers April 28th, 2016
Introducing the RE標ORK Bio-inspired Robotics Summit in Berlin April 27th, 2016